Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-7.21%
-1.78%
-1.33%
-5.70%
-8.05%
Most Trending
-7.21%
-1.78%
-1.33%
-5.70%
-8.05%
08 Dec 2025$WVE surged after Wave Life Sciences delivered overwhelmingly positive interim data from its Phase 1 INLIGHT obesity trial. The company reported meaningful fat loss comparable to GLP 1 treatments without muscle loss and without multiple injections, which ignited a historic spike in both price and volume. With trading activity exploding far above its typical averages, sentiment turned euphoric as traders reacted to what could be a breakthrough mechanism in the weight loss space.
$CETX climbed sharply as Confluent related headlines triggered sympathy momentum across several data infrastructure and AI adjacent names. With IBM reported to be in advanced discussions for a major acquisition in the space, traders piled into surrounding tickers with high beta exposure. The extremely unusual volume added fuel to the rally as momentum algorithms pushed the stock further into the green.
$WBUY gained strongly on news of its expanded collaboration with WITSTAR, opening a new channel for cross border education and cultural exchange between Malaysia and China. Traders responded quickly to the growth angle, as the partnership signaled a tangible expansion path for the online commerce and advisory business. The volume spike well beyond normal trading activity confirmed rising attention from retail momentum players.
$GPCR soared after Structure Therapeutics released standout Phase 2 data showing strong weight loss results for its oral GLP 1 agonist aleniglipron. With weight loss drugs commanding massive market attention, the idea of a promising pill based alternative sparked aggressive buying. The sharp increase in volume and the narrative of potential best in class performance drove traders into the name throughout the session.
$FULC moved sharply higher following positive Phase 1b results in its sickle cell program. Traders reacted quickly to the encouraging clinical updates, although the RSI reading sliding into overbought territory signaled that momentum may be heating up faster than fundamentals alone would justify. Even so, volume swelled above the average as speculative interest grew.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
TopRated
Pro Members
